RT @ontrack9_oktogo: $CYTR the failure of @DrPatSoonShiong can be measured in how many patients were treated with doxorubicin while less ca…
RT @ontrack9_oktogo: $CYTR the failure of @DrPatSoonShiong can be measured in how many patients were treated with doxorubicin while less ca…
$CYTR the failure of @DrPatSoonShiong can be measured in how many patients were treated with doxorubicin while less cardio toxic Aldoxorubicin sat on the shelf hidden in redundant phase I trials so it would not compete with his other invention Abraxane htt
RT @ontrack9_oktogo: https://t.co/Y5QTmD5J8b @DrPatSoonShiong is causing + creating problems not only for shareholders of $IBRX & $CYTR -…
https://t.co/Y5QTmD5J8b @DrPatSoonShiong is causing + creating problems not only for shareholders of $IBRX & $CYTR - but his delay in filing New Drug Application for Aldoxorubicin does actually have ethical + moral ramifications on a global scale. Pla
RT @ontrack9_oktogo: @DrPatSoonShiong @ParikPatelCFA $4200 dose for Abraxane! But You chose to use $CYTR's Aldoxorubicin in trials. Why? Do…
RT @ontrack9_oktogo: @DrPatSoonShiong 🤏🙉is using 2 drugs from 2 different companies as his Triangle Offense against cancer ALT 803 is now A…
@DrPatSoonShiong 🤏🙉is using 2 drugs from 2 different companies as his Triangle Offense against cancer ALT 803 is now Anktiva + $CYTR's Aldoxorubicin is Trojan Horse. Aldoxorubicin could be used as a single monotherapy for 17 clinical cancer indications. ht
RT @ontrack9_oktogo: @DrPatSoonShiong @ParikPatelCFA $4200 dose for Abraxane! But You chose to use $CYTR's Aldoxorubicin in trials. Why? Do…
@DrPatSoonShiong @ParikPatelCFA $4200 dose for Abraxane! But You chose to use $CYTR's Aldoxorubicin in trials. Why? Does the molecular structure of the hydrazone linker bind to Albumin better in Aldoxorubicin versus using Albumin fragments in Abraxane? htt
Although doxorubicin is an effective therapy in sarcoma, its dose-dependent risk of cardiotoxicity seen with cumulative doses 300–950 mg/m2 remains a significant safety concern. https://t.co/F7G1fwKxND
A new drug, based on doxorubicin shows promise in trials in the US. Nice to see acknowledgment that new more effective treatments are ‘desperately’ needed for relapsed soft tissue sarcomas (boy don’t we know it!). Great to see progress https://t.co/SZDp634
RT @SuzieSiegel: Dr. Charles Forscher @CedarsSinai & colleagues say "#aldoxorubicin may represent the superior anthracycline in the treatme…
Dr. Charles Forscher @CedarsSinai & colleagues say "#aldoxorubicin may represent the superior anthracycline in the treatment of advanced" soft-tissue #sarcoma. I hope we get final data @ASCO. https://t.co/aGoOb0QAhE
RT @SarcomaAlliance: The results of trials of aldoxorubicin, and potential use for soft tissue sarcoma, are discussed in this article. http…
The results of trials of aldoxorubicin, and potential use for soft tissue sarcoma, are discussed in this article. https://t.co/ZPVxbPN5qg https://t.co/ZPVxbPN5qg
RT @TomSilver39: $CYTR Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas https://t.co/b…
$CYTR Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas https://t.co/bKGUbXclQG